Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000531826 | SCV000627574 | likely benign | Long QT syndrome | 2024-12-24 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002350180 | SCV002650206 | likely benign | Cardiovascular phenotype | 2020-01-27 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Prevention |
RCV003419923 | SCV004116418 | uncertain significance | CACNA1C-related disorder | 2022-10-16 | criteria provided, single submitter | clinical testing | The CACNA1C c.5729G>A variant is predicted to result in the amino acid substitution p.Arg1910Gln. This variant was reported in a study of ion channel-related genes in individuals with autism spectrum disorder (Supplementary Table 1, Lee et al 2021. PubMed ID: 34712263). This variant is reported in 0.097% of alleles in individuals of East Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/12-2795380-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |